Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Aero Fly Coronary Intravascular Lithotripsy (IVL) Cat
Shockwave Medical, Inc. · Decision date Feb 20, 2026
What did the FDA approve?
FDA records P200039/S019 as a supplement to PMA P200039, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Feb 20, 2026.
FDA approval order statement
approval for the C2 Aero Fly Coronary Intravascular Lithotripsy (IVL) Catheter with higher pulse rate and shorter pause time than the C2 Aero Coronary Intravascular Lithotripsy (IVL) Catheter approved under P200039/S015
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 20, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P200039/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Shockwave Medical, Inc.
- Product code
- QMG
- Decision code
- APPR
- Decision date
- Feb 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Shockwave intravascular lithotripsy system.
- Applicant
- Shockwave Medical, Inc.
- Product code
- QMG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200039. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200039 · Original PMA
Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter
P200039/S018 · Related supplement
Shockwave lntravascular Lithotripsy {IVL) System with Shockwave C2/ C2+/ C2 Aero Coronary IVL Catheter
P200039/S019 received
Application receipt date recorded by FDA.
P200039/S019 · FDA decision
Normal 180 Day Track
P200039/S020 · Related supplement
Shockwave lntravascular Lithotripsy (IVL) System with Shockwave C2 Aero Coronary IVL Catheter
P200039/S022 · Related supplement
Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter; Sh
P200039/S021 · Related supplement
Shockwave lntravascular Lithotripsy (IVL) System with Shockwave C2 / C2+ / C2 Aero/ C2 Aero Fly Coronary IVL Catheter
P200039/S023 · Related supplement
Shockwave lntravascular Lithotripsy (IVL) System with Shockwave C2 Aero Fly Coronary IVL Catheter
P200039/S025 · Related supplement
SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH SHOCKWAVE C2/C2+ CORONARY IVL CATHETER
Timeline entries are records held by MedtechLedger for P200039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Shockwave Medical, Inc. | PMA approval | Feb 12, 2021 | FDA | |
| Shockwave Medical, Inc. | PMA supplement | Oct 14, 2025 | FDA | |
| Shockwave Medical, Inc. | PMA supplement | Mar 5, 2026 | FDA | |
| Shockwave Medical, Inc. | PMA supplement | May 7, 2026 | FDA | |
| Shockwave Medical, Inc. | PMA supplement | Jun 24, 2026 | FDA | |
| Shockwave Medical, Inc. | PMA supplement | Jun 29, 2026 | FDA | |
| Shockwave Medical, Inc. | PMA supplement | Sep 11, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Shockwave Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5403 Betsy Ross Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P200039/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records